Glycostem

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Disc Goes Public As Gemini Downshifts F

U. Of Texas Research Branch Maintains Hectic Partnering Pace The increasingly busy University of Texas MD Anderson Cancer Center inked three new alliances with biopharmaceutical companies in the pas

Who: Merck & Co./Artiva Biotherapeutics What: Merck & Co. signed a partnership and option-to-license agreement to access Artiva’s off-the-shelf natural killer cell and chimeric antigen receptor tec